| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Immunobiology Research Center, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115; and
Instituto Gulbenkian de Ciência, Oeiras, Portugal
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
-mediated E-selectin and VCAM-1, but not ICAM-1 expression, as tested at the RNA and protein level. Heme-driven HO-1 expression had similar effects to those of overexpressed HO-1. In addition, HO-1 inhibited the activation of NF-
B, a transcription factor required for TNF--mediated up-regulation of these genes in EC. Bilirubin and/or Fe2+ chelation mimicked the effects of HO-1, whereas biliverdin or carbon monoxide did not. In conclusion, HO-1 inhibits the expression of proinflammatory genes associated with EC activation via a mechanism that is associated with the inhibition of NF-B activation. This effect of HO-1 is mediated by bilirubin and/or by a decrease of free intracellular Fe2+ but probably not by biliverdin or carbon monoxide. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
(4), or IL-1
(5), EC modify their phenotype and become activated (reviewed in Ref. 6), promoting adhesion, activation, and transmigration of circulating leukocytes (reviewed in Refs. 1 and 7). This is accomplished primarily via the up-regulation of a series of proinflammatory genes that promote leukocyte adhesion activation and transmigration. These include the adhesion molecules E-selectin (CD62E) (8), P-selectin (CD62P) (9), ICAM-1 (CD54) (3), and VCAM-1 (CD106) (10). The expression of these genes is regulated primarly at the transcriptional level through a mechanism that requires the activation of the transcription factor NF-B (11, 12). To avoid unfettered leukocyte activation and transmigration in a manner that would cause tissue injury, the expression of proinflammatory genes associated with EC activation must be strictly controlled (13). One of the mechanisms by which this occurs relies on the expression by activated EC of anti-inflammatory genes. We refer to these genes as protective genes based on their dual ability to inhibit the expression of proinflammatory genes associated with EC activation and to protect EC from undergoing apoptosis (13). We have hypothesized that the stress-responsive gene heme oxygenase-1 (HO-1) (hmox-1/hsp-32) acts in such a manner.
We have previously shown that HO-1 protects EC from undergoing apoptosis (14). We now tested whether HO-1 would also inhibit the expression of proinflammatory genes associated with EC activation. Such an effect would be consistent with the potent anti-inflammatory and cytoprotective effects attributed to the expression of HO-1 in an increased number of experimental models of acute and/or chronic inflammation in vivo.
Under inflammatory conditions, HO-1 becomes the rate-limiting enzyme in the catabolism of heme into biliverdin, free Fe2+, and CO (15) (reviewed in Ref. 16). Biliverdin is subsequently catabolized into bilirubin by biliverdin reductase (17) (reviewed in Ref. 18). Free Fe2+ up-regulates the expression of ferritin, an Fe2+-sequestering protein (19, 20) and activates an ATPase iron pump which also decreases the level of intracellular Fe2+ (21, 22). Expression of HO-1 has potent anti-inflammatory (23) and antithrombotic (24) effects in monocyte/macrophages as well as antiapoptotic effects in EC (25). These are exerted, not only via heme degradation, but also through the generation of bilirubin (26), CO (23, 24, 25), and ferritin (19), as well as the activation of ferroportin (21).
We demonstrate in this study that expression of HO-1 in cultured EC inhibits the ability of proinflammatory cytokines such as TNF- or IL-1 to induce the expression of adhesion molecules associated with EC activation. This effect can be mimicked by bilirubin or depletion of free Fe2+. The likely mechanism by which these effects occur involves the inhibition of NF-B activation, a transcription factor strictly required for the transcription of these proinflammatory genes.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Primary bovine aortic EC (BAEC) and porcine aortic EC (PAEC) were isolated and cultured as described before (11). Alternatively, BAEC were purchased from Cell Systems Corporation (Kirkland, WA) and cultured in MCDB-131 (Life Technologies, Paisley, U.K.) supplemented with 10% heat-inactivated FCS (Life Technologies), 10 mM L-glutamine (Life Technologies), 50 U/ml penicillin (Life Technologies), and 50 µg/ml streptomycin (Life Technologies). When required, fungizone (2.5 µg/ml) was added (Life Technologies). Pooled HUVEC (Clonetics, Zurich, Switzerland) were cultured in EBM-2 medium (Clonetics), supplemented with 1% heparin, 0.04% hydrocortisone, 50 µg/ml gentamicin sulfate/amphotericin, 0.1 ng/ml ascorbic acid, 0.5% human fibroblast growth factor B, 0.1% human recombinant endothelial growth factor (vascular), 0.1% human recombinant epidermal growth factor, and 0.1% insulin-like growth factor (Clonetics).
Reagents
Human rTNF-, IL-1 (R&D Systems, Minneapolis, MN), or bacterial LPS (Escherichia coli serotype 0127:B8; Sigma-Aldrich, St. Louis, MO) were used to induce the expression of proinflammatory genes in cultured EC (6–8 h for protein expression; 2 h for mRNA expression). Desferoxamine mesylate (DFO; 50–500 µM; Sigma-Aldrich) was used to chelate iron (incubation for 16 h before exposure to TNF-). DFO was prepared at a stock solution of 100 mM in sterile distilled water and kept frozen at -20°C until used. Alternatively, iron chelation was achieved using salicylaldehyde isonicotinoyl hydrazone (SIH; 100 µM) (27) (a kind gift from Dr. P. Ponka (McGill University, Montreal, Quebec, Canada)). SIH was prepared and kept at 4°C until used, as described elsewhere (27). Hemin (Frontier Scientific, Logan, UT) was dissolved in 0.2 N NaOH, neutralized to pH of 7.4 using 1 N HCl, and stored at -20°C until used. Hemin was used to induce HO-1 expression in cultured EC as described by Balla et al. (19). Briefly, cultured EC were washed once in HBSS containing Ca2+ and Mg2+ (Life Technologies) and exposed (1 h) to hemin (5, 10, or 25 µM) in HBSS. EC were then cultured overnight in EBM-2 and supplemented as described above. The HO-1 inhibitor tin protoporphyrin IX (Frontier Scientific) was prepared and used in a similar manner. Biliverdin hydrochloride (ICN Biomedicals, Aurora, OH) was diluted in 25% DMSO at a stock solution of 2.5 mM and kept frozen until used. Bilirubin (Frontier Scientific) was dissolved in 0.2 N NaOH, neutralized to pH 7.4 using 1 N HCl, and used fresh.
Recombinant adenoviruses
The recombinant -galactosidase (-gal) adenovirus was a kind gift from Dr. R. Gerard (University of Texas Southwest Medical Center, Dallas, TX). The recombinant adenovirus expressing the rat HO-1 cDNA has been described elsewhere (28). Recombinant adenoviruses were produced in human embryonic kidney 293 cells (American Type Culture Collection, Manassas, VA), extracted, and purified through two cesium chloride gradient ultracentrifugations, and their titer was determined by limiting dilution in human embryonic kidney 293 cells as described before (12). Confluent HUVEC, BAEC, and PAEC were infected with a multiplicity of infection of 100, 200, and 400 PFU/cell, respectively, as described elsewhere (11).
Flow cytometry
Transduced or nontransduced confluent HUVEC in six-well plates were treated with recombinant human TNF- (10 ng/ml; 6 h; R&D Systems) and harvested by trypsin digestion (100 µl/well; 0.05% in PBS). Cells were collected and washed in PBS (pH 7.2; 5% FCS and 0.01% NaN3; 4°C) and incubated (1 x 102 cells in 100 µl; 30 min; 4°C) with mouse anti-human E-selectin (clone BBIG-E6; 13D5), ICAM-1 (clone BBIG-1; 11C81), or VCAM-1 (clone BBIG-V1; 4B2) mAbs (R&D Systems), 2 µg/ml in PBS, 5% FBS, and 0.1% NaN3. Mouse anti-human TNF-R1 (clone 16803) and TNF-R2 (clone TR75-89) mAbs (R&D Systems) were used at a concentration of 20 µg/ml (60 min; 4°C). After washing in PBS, 5% FBS, and 0.01% NaN3 (300 x g; 5 min), cells were stained (30 min; 4°C) with an FITC-labeled polyclonal goat anti-mouse IgG Ab (Sigma-Aldrich). Fluorescent labeling was evaluated using a FACSort equipped with CellQuest software (BD Biosciences, Palo Alto, CA). Specific labeling was compared with nonspecific staining using FITC-labeled isotype-matched control mAb. Modulation of the expression of the different molecules analyzed was assessed, comparing the expression on TNF--treated vs untreated cells.
Cellular ELISA
HUVEC were cultured in 0.2% bovine gelatin (Life Technologies)-coated 96-well culture plates (Life Technologies) in culture medium, as described above. One or 2 days postconfluence, cells were stimulated with human rTNF- (10 ng/ml; 6 h), washed twice in PBS/0.05% Tween 20 (Sigma-Aldrich), and fixed in 0.01% glutaraldehyde (Sigma-Aldrich) in PBS/0.05% Tween 20 (30 min; 4°C). Nonspecific binding sites were saturated with 5% skimmed milk (Primor, Lisbon, Portugal) in PBS/0.05% Tween 20 (60 min; room temperature (RT)). Cells were washed twice in PBS/0.05% Tween 20 and incubated (1–2 h; 37°C) in the presence of anti-E-selectin (R&D Systems), ICAM-1 (R&D Systems), or VCAM-1 (R&D Systems) mAbs (2 µg/ml; 1–2 h; RT) in PBS/5% skimmed milk/0.05% Tween 20 (Sigma-Aldrich). In some experiments, VCAM-1 was detected using a goat anti-human VCAM-1 Ab (Santa Cruz Biotechnology, Santa Cruz, CA). Cells were washed twice in PBS/0.05% Tween 20, and primary Abs were detected using HRP-labeled goat anti-mouse Fab' (0.1 µg/ml; 1 h; RT) (Pierce, Rockford, IL). HRP was revealed using ortho-phenyldiamine (Sigma-Aldrich) and H2O2 (0.03%) in citrate buffer (pH 4.9). Absorbance was measured at 
= 490 nm. The relative level of expression of the different molecules detected was expressed as OD units ( = 490).
Cell extracts and Western blot analysis
Cell extracts were prepared and subjected to electrophoresis as described elsewhere (11). HO-1 was detected using a rabbit anti-human HO-1 polyclonal Ab (StressGen Biotechnologies, Victoria, BC, Canada). For the detection of E-selectin, ICAM-1, and VCAM-1, protein extracts were not subjected to 2-ME reduction. E-selectin was detected using the mAb h4/18 (kind gift from M. Gimbrone (Brigham and Women’s Hospital, Boston, MA)). ICAM-1 and VCAM-1 were detected using rabbit anti-human ICAM-1 and VCAM-1 Abs (Santa Cruz Biotechnology), respectively. -Tubulin was detected using anti-human -tubulin mAb (Boehringer Mannheim, Indianapolis, IN). Total and activated/phosphorylated forms of extracellular signal-regulated kinases (ERK-1 and -2), c-Jun N-terminal kinases (JNK-1, -2, and 3), and p38 mitogen-activated protein kinases (MAPK) were detected using rabbit polyclonal Abs directed against the total or phosphorylated forms of these MAPK, according to the manufacturer’s suggestions (Cell Signaling, Beverly, MA). Primary Abs were detected using HRP-conjugated donkey anti-rabbit or goat anti-mouse or rabbit IgG secondary Abs (Pierce). Peroxidase activity was visualized using the ECL assay (Amersham, Arlington Heights, IL), according to the manufacturer’s instructions and stored in the form of photoradiographs (Biomax MS; Eastman Kodak, Rochester, NY). When indicated, membranes were stripped (62.5 mM Tris-HCl (pH 6.8), 2% SDS, and 100 mM 2-ME; 30 min; 50°C). Phosphorylated ERK, JNK, and p38 were normalized to the total amount of total ERK, JNK, and p38, detected in the same membrane.
Cytotoxicity assays
HUVEC were exposed to hemin, as described above (19), collected by trypsin digestion (Invitrogen, San Diego, CA) and resuspended in PBS, 3% FCS, and 10 µg/ml propidium iodide (15 min; RT) (Sigma-Aldrich). Cells were analyzed for viability by flow cytometry (1 x 104 cells/sample) using a FACScan cytometer (BD Biosciences) equipped with CellQuest software (BD Biosciences). For positive controls, HUVEC were exposed to 5% Triton X-100 (Sigma-Aldrich) following trypsinization.
Fluorescent microscopy
HUVEC were cultured on gelatinized glass slides (PerkinElmer, Wellesley, MA), fixed in 100% acetone (Sigma-Aldrich), and stained with an anti-HO-1 polyclonal Ab (2 µg/ml; SPA-896; StressGen Biotechnologies). Primary Ab was detected using Alexa Fluor 594-labeled goat anti-rabbit Ab (Molecular Probes, Eugene, OR). Fluorescent labeling was detected (ex = 590 nm; em = 617 nm) using a DMR2 microscope (Leica, Deerfield, IL) equipped with Metamorph3 software (Universal Imaging, Downingtown, PA).
Northern blot
HUVEC were treated with TNF- (2 h), and RNA was extracted using TRIzol, according to the manufacturer’s suggestions (Life Technologies). Total RNA was separated on a 1.3% agarose formaldehyde gel, transferred overnight to Hybond-N nylon membranes (Amersham), and analyzed by specific hybridization to radiolabeled cDNA probes for human E-selectin (kind gift from Dr. T. Collins (Children’s Hospital, Boston, MA)), ICAM-1 (kind gift from Dr. T. Collins), VCAM-1 (kind gift from Dr. T. Collins), and rat HO-1 as described before (11). All probes were labeled with [-32P]dATP (Amersham) using a random primer labeling kit (Stratagene, La Jolla, CA). Membranes were probed for GAPDH to control for equal RNA loading. Digital images were obtained using a PhosphorImager (Storm Imager; Molecular Dynamics, Sunnyvale, CA). Intensity of [-32P]dATP labeling was quantified using ImageQuant software (Amersham).
CO exposure
Briefly, CO at a concentration of 1% (10,000 ppm) in compressed air plus 5% CO2 was mixed with balanced air (21% O2 plus 5% CO2) in a stainless-steel mixing cylinder before entering the exposure chamber. CO concentrations were controlled by varying the flow rates of CO in a mixing cylinder before delivery to the chamber. Because the flow rate is primarily determined by the O2 flow, only the CO flow was changed to deliver the final concentration to the exposure chamber. A CO analyzer (Interscan, Chatsworth, CA) was used to measure CO levels in the chamber. Cells were exposed to CO 16 h before stimulation with TNF- and continuously thereafter.
Transient transfections and reporter assays
BAEC were seeded at 200 x 103 cells per well in six-well plates and transiently transfected 24 h after using Lipofectamine 2000 (Life Technologies). Briefly, Lipofectamine 2000 (2 µl) was incubated (20 min; RT) with purified plasmid DNA (3 µg) in MCDB-131 (200 µl). Cells were washed in MCDB-131, and BAEC were exposed to DNA/Lipofectamine (2 h) in a final volume of 1 ml of MCDB-131. DNA/Lipofectamine was removed, and cells were cultured for an additional 48 h in MCDB-131, 10% heat-inactivated FCS, 10 mM L-glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin (Life Technologies). Cells were exposed to human rTNF- (10 ng/ml; 8 h), and cell extracts were obtained using the Promega (Madison, WI) cell culture lysis reagent extraction kit, according to the manufacturer’s instructions. Cell extracts were assayed for -gal (Galacto-Light; Applied Biosystems, Tropix, Bedford, MA) and luciferase activity (luciferase assay system; Promega), according to the manufacturer’s instructions. Luciferase and -gal activities were measured using a MicroLumat Plus luminometer (LB96V; Berthold, Bad Wildbad, Germany). Luciferase activity was normalized for -gal as follows: luciferase activity/-gal activity x 100. Normalized luciferase activity is shown in arbitrary units.
Expression plasmids
The PSV--gal cDNA was driven by the SV40 early promoter and enhancer (E1081; Promega). The rat HO-1 cDNA was driven by the CMV enhancer/promoter (pcDNA3/HO-1) (29). The NF-B luciferase reporter has been described elsewhere (30).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To assess the effect of HO-1 overexpression on the up-regulation of proinflammatory genes associated with EC activation, we have used a HO-1 recombinant adenovirus, allowing to achieve overexpression of HO-1 in virtually 100% of cultured EC. Maximal transduction efficiency was observed between 100 and 400 PFU of recombinant adenovirus per cell, i.e., 100 PFU for HUVEC, 200 PFU for BAEC (data not shown), or 400 PFU for PAEC (Fig. 1A). Expression of HO-1 was confirmed by Western blot 24 h after transduction (Fig. 1B). Expression of -gal recombinant adenovirus did not induce HO-1 expression (Fig. 1).
|
stimulation in nontransduced or -gal recombinant adenovirus-transduced EC (Fig. 2). VCAM-1 expression was significantly inhibited in EC transduced with a HO-1 recombinant adenovirus, compared with nontransduced or -gal-transduced EC (Fig. 2). Similar results were observed when the expression of these proteins was detected by Western blot (Fig. 3).
|
|
-gal-transduced EC expressed basal levels of ICAM-1 at the cell surface, which were significantly increased when EC were exposed to TNF- (Fig. 2). ICAM-1 expression was significantly increased in HO-1, but not in -gal recombinant adenovirus-transduced EC compared with nontransduced controls (Fig. 2). TNF- did not further increase ICAM-1 expression in HO-1-transduced EC (Fig. 2). Similar results were observed when ICAM-1 expression was detected by Western blot except that the basal level of ICAM-1 expression was somehow not detectable by Western blot (Fig. 3).
In nontransduced or -gal-transduced EC, the level of expression of these adhesion molecules increased in a dose-dependent manner when the cells were exposed to TNF-, i.e., the higher the TNF- concentration, the higher the level of expression (Fig. 4). HO-1-transduced EC required a 10- to 100-fold higher concentration of TNF- to induce a similar level of E-selectin or VCAM-1 expression, compared with nontransduced or -gal-transduced EC (Fig. 4A). Heat inactivation of the HO-1 recombinant adenovirus blunted its inhibitory effect (Fig. 4B), excluding the possibility that the inhibitory effect of this recombinant adenovirus was related to contamination by endotoxin.
|
-mediated E-selectin and VCAM-1 mRNA expression, compared with nontransduced or -gal-transduced EC (Fig. 5). Expression of HO-1 had no significant effect on ICAM-1 mRNA expression (Fig. 5). EC that overexpressed HO-1 required 10–100x higher concentrations of TNF- to achieve a similar level of E-selectin and VCAM-1 mRNA expression, compared with nontransduced or -gal-transduced EC (Fig. 6).
|
|
-mediated up-regulation of VCAM-1
Exposure of EC to hemin (5 or 10 µM) induced high levels of HO-1 expression, as detected by Western blot or immunocytochemistry (Fig. 7, A and B) (19). HO-1 expression was noticed in the cytoplasm as well as in the nuclei, as revealed by immunocytochemistry (Fig. 7B). Exposure of EC to hemin (5–10 µM) did not result in detectable cytoxicity (Fig. 7C), a result consistent with those of others (19). TNF--mediated expression of VCAM-1 was significantly inhibited in EC exposed to hemin, compared with control-treated EC (Fig. 7D). Expression of E-selectin and ICAM-1 were not inhibited to the same extent of VCAM-1 (Fig. 7D). Similar results were obtained in EC exposed to cobalt protoporphyrin IX, a synthetic protoporphyrin that also induces the expression of HO-1 (data not shown). Tin protoporphyrin IX, a synthetic protoporphyrin that blocks HO-1 activity, did not inhibit VCAM-1 expression (data not shown).
|
Expression of HO-1 results in the up-regulation of ferritin (19) (data not shown) and is coupled to the activation of an ATPase iron pump (21, 22). Given that ferritin and an ATPase iron pump act to reduce the level of intracellular Fe2+, we asked whether reduction of the reactive pool of cellular Fe2+ would mimic the effect of HO-1. Iron chelation by DFO or the permeable iron chelator SIH significantly inhibited E-selectin as well as VCAM-1 expression in a similar manner to HO-1 (Fig. 8). DFO and, to a lesser extent, SIH also inhibited ICAM-1 expression (Fig. 8).
|
We asked whether biliverdin and/or bilirubin could account for the ability of HO-1 to modulate the expression of E-selectin, and/or VCAM-1 in EC. Bilirubin inhibited the expression of E-selectin and VCAM-1 in a manner that was similar to that of HO-1 (Fig. 9A). Bilirubin also inhibited the expression of ICAM-1 (Fig. 9A). When used at a similar concentration, biliverdin did not modulate the expression of E-selectin, VCAM-1, or ICAM-1 (Fig. 9B).
|
Because of the potent anti-inflammatory effects of CO in monocyte macrophages (23), we asked whether the ability of HO-1 to modulate the expression of the proinflammatory genes E-selectin and VCAM-1 in EC was also due to CO. The data illustrated in Fig. 10 suggest that this is not the case. Pre-exposure of EC to exogenous CO (100 or 250 ppm; 16 h) had no significant effect in terms of modulating TNF--driven E-selectin, ICAM-1, or VCAM-1 expression in EC (Fig. 10). Similar results were obtained using 1,000 or 10,000 ppm CO (data not shown). We cannot rule out that a different dose or dosing schedule of CO would lead to inhibition.
|
B
We asked by which mechanism HO-1 modulated TNF--driven E-selectin and VCAM-1 expression in EC. One possibility would be that HO-1 modulates the level of expression of TNFRs at the EC surface, thus inhibiting the ability of TNF- to trigger E-selectin or VCAM expression. However, we found that the level of expression of TNFR-1, the predominant TNFR in EC, was not inhibited in EC transduced with an HO-1 recombinant adenovirus, compared with -gal-transduced or nontransduced EC (Fig. 11A). We then asked whether HO-1 would also inhibit the ability of IL-1 to up-regulate the expression of E-selectin or VCAM. We found that HO-1 inhibited IL-1-mediated VCAM-1 and, to a lesser extent, E-selectin expression (Fig. 11B).
|
and IL-1 induce the expression of proinflammatory genes associated with EC activation through a mechanism that is dependent on the activation of the transcription factor NF-B (11, 30, 31), we tested whether HO-1 inhibited NF-B activity in EC. We monitored NF-B transcription activity in EC transiently transfected with an NF-B luciferase reporter. In EC exposed to TNF-, NF-B activity increased by 8- to 12-fold, compared with controls not exposed to TNF- (Fig. 12). TNF- did not modulate the transcription activity of SV40-driven -gal or luciferase reporters, used to monitor variations in transfection efficiency in this assay (data not shown). Overexpression of HO-1 inhibited TNF--driven NF-B luciferase activity by 50–75%, compared with control EC (Fig. 12A). This effect was dose dependent, in that increasing levels of HO-1 led to a corresponding decrease in NF-B activation (Fig. 12A). HO-1 did not modulate the transcription activity of SV40-driven -gal or luciferase reporters (data not shown).
|
B transcription activity was linked to its ability to generate CO, biliverdin, or bilirubin, and/or the reduction of intracellular Fe2+ levels. Both iron chelation by DFO or exogenous bilirubin inhibited TNF--mediated NF-B transcription activity (Fig. 12, C and D). Neither exogenous CO nor biliverdin modulated NF-B activation (Fig. 12, B and E). HO-1 promotes the activation of the p38 MAPK signal transduction pathway
Expression of E-selectin, ICAM-1, and VCAM-1 can be modulated by the activation of MAPK signal transduction pathways. Because we found that the expression of HO-1 can modulate the p38 MAPK signal transduction pathway (23, 25), we asked whether this would occur in EC that overexpress HO-1. Expression of HO-1 increased TNF--mediated p38 activation, but not the activation of JNK or ERK (Fig. 13). Whether activation of p38 MAPK plays a role in the inhibition of E-selectin or VCAM-1 expression by HO-1 remains to be established.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The molecular basis of the anti-inflammatory action of HO-1 remains to be fully elucidated, but so far, CO seems to be responsible for most of the anti-inflammatory effects attributed to HO-1. For example, expression of HO-1 in monocyte/macrophages down-regulates the expression of proinflammatory cytokines such as TNF- and up-regulates the expression of the anti-inflammatory cytokine IL-10 (23). TNF- is a key mediator in the initiation of certain inflammatory reactions (37), whereas IL-10 is anti-inflammatory. CO mimics HO-1 in this respect, suggesting that it mediates its anti-inflammatory effect (23). More recently, the anti-inflammatory effect of IL-10 itself has been shown to act via the up-regulation of HO-1 and the generation of CO (38). CO also acts in an antithrombotic manner by promoting vasodilation via its action on smooth muscle cells (39), inhibiting platelet activation (40, 41) and suppressing the plasminogen activator inhibitor type 1 (serpin-1) expression, a prothrombotic molecule, in monocyte/macrophages (24). These actions of CO are likely to contribute to the anti-inflammatory effect of HO-1.
HO-1 has cytoprotective/antiapoptotic effects in a variety of cell types, including in EC (19, 25, 42). The physiological raison d’être of this may relate to the fact that free heme generated during inflammatory reactions primes EC to oxidative stress-mediated cytotoxicity (19). Therefore, expression of HO-1 would act to protect EC from the cytotoxic effects of high levels of free heme (42, 43). We have shown that the cytoprotective/antiapoptotic action of HO-1 is mediated via CO (14, 25). Given that EC apoptosis can exacerbate inflammatory reactions (44), the antiapoptotic action of CO may also contribute to its anti-inflammatory effect (43).
In the present study, we asked whether HO-1 would have additional functions that could contribute to its anti-inflammatory effect. We found that overexpression of HO-1 in EC significantly inhibits the ability of TNF- to induce the expression of proinflammatory adhesion molecules associated with EC activation, i.e., E-selectin and VCAM-1 (Figs. 2–7). This effect was also observed when the expression of HO-1 was induced by heme (Fig. 7), suggesting that it is physiologically relevant. However, contrary to HO-1 overexpression, induction of HO-1 by heme did not result in the inhibition of E-selectin expression (Fig. 7). Whether this is due to a qualitative and/or a quantitative difference between overexpressing HO-1 or inducing HO-1 expression by heme, which occurs in the context of a pro-oxidant response, remains to be established.
Contrary to the anti-inflammatory effect of HO-1 in monocyte/macrophages (23), its ability to inhibit the expression of proinflammatory adhesion molecules in EC is probably not mediated by CO. This is suggested by the observation that exogenous CO does not mimic the effect of HO-1 in terms of inhibiting E-selectin or VCAM-1 expression (Fig. 10). Instead, we found that bilirubin (Fig. 9) and/or Fe2+ chelation (Fig. 8) can mimic this effect of HO-1. This suggests that the ability of HO-1 to inhibit the expression of these adhesion molecules is mediated by bilirubin and/or by the decrease of intracellular Fe2+ levels associated with HO-1 activity but not by CO.
Our present finding that HO-1 inhibits the expression of E-selectin and VCAM-1 is in keeping with those of others, suggesting that induction of HO-1 by cobalt protoporphyrin IX also inhibits the expression of these genes in vivo (45, 46). However, in those studies, it was not clear whether HO-1 acted directly on EC or whether this effect was indirect, i.e., mediated via the anti-inflammatory effect of HO-1 on monocyte/macrophages, thereby decreasing the stimulus, e.g., TNF-, leading to the expression of these adhesion molecules in EC. We now demonstrate that, independently of its anti-inflammatory effects in monocyte/macrophages, HO-1 acts directly in EC to inhibit the expression of these adhesion molecules (Figs. 1–7). Moreover, we found that HO-1 decreased the E-selectin and VCAM-1 expression at the mRNA level (Figs. 5 and 6) without interfering with the mRNA half-life (data not shown). This suggests that HO-1 inhibits the accumulation of these mRNAs by interfering with their rate of transcription. This notion is further supported by the observation that HO-1 inhibits the activity of the transcription factor NF-B (Fig. 12), which is strictly required for the expression of E-selectin and VCAM-1 in EC (11, 47).
While the mechanism by which HO-1 inhibits NF-B activation remains to be elucidated, we can only speculate how this may occur. TNF--mediated NF-B activation is thought to involve an oxidative step (31, 47), required for triggering the phosphorylation/degradation of the natural NF-B cytoplasmic inhibitor IB (reviewed in Ref. 48) by the IB kinase signalosome (49). At first, our data would be consistent with the notion that, by reducing the levels of free radicals in the cell, the antioxidant bilirubin (50) and/or the reduction of the levels of intracellular Fe2+ could account for this effect of HO-1 (Fig. 12). However, we have recently found that overexpression of HO-1 in EC does not inhibit IB phosphorylation/degradation or nuclear translocation of the NF-B heterodimer p65/RelA (our unpublished data). This suggests that HO-1 inhibits NF-B activity downstream of these events. We have previously demonstrated that this can occur at the level of p65/RelA phosphorylation (51) and have preliminary evidence to suggest that HO-1 may act in a similar manner (our unpublished data).
Inhibition of NF-B transcription activity by HO-1 was only partial, i.e., 50–75% inhibition vs control EC (Fig. 12). This effect is consistent with the extent of inhibition of E-selectin and VCAM-1 at both the protein (Figs. 2–4) and mRNA (Figs. 5 and 6) levels. Although speculative, this may have important implications for the overall biological function of HO-1, because we have recently shown that, to prevent EC apoptosis, HO-1 requires that NF-B activation must be maintained above a certain threshold level (29). This level of NF-B activity seems to be required to sustain the expression of a subset of NF-B-dependent antiapoptotic genes that interact functionally with HO-1-derived CO to prevent EC apoptosis (29). Thus, if HO-1 would suppress NF-B activity below this threshold level, the antiapoptotic action of HO-1 would be disabled, which would most probably have detrimental effects (44). We propose that HO-1 has reached a functional compromise in that it blocks NF-B-mediated transcription activity in a manner that inhibits the expression of a subset of NF-B dependent genes, e.g., E-selectin and VCAM-1, but allows the expression of other NF-B-dependent genes, e.g., ICAM-1, including those required to support its antiapoptotic action (29). Whether this selective effect is purely due to the extent of NF-B inhibition or whether there are additional mechanisms that could account for it is not clear.
In contrast to HO-1, bilirubin and to some extent Fe2+ chelation also inhibit the expression of ICAM-1 (Figs. 8 and 9). It seems unlikely that this difference is related to a distinct mechanism of action of bilirubin compared with HO-1. Rather, the concentration of bilirubin or the extent of Fe2+ depletion generated by the action of HO-1 may not be as great as that permitted by the exogenous administration of bilirubin or DFO.
In conclusion, we have demonstrated that HO-1 can inhibit the expression of a subset of proinflammatory genes associated with EC activation. This anti-inflammatory effect involves the inhibition of NF-B activity, a transcription factor strictly required for the expression of most proinflammatory genes associated with EC activation. Contrary to other anti-inflammatory effects attributed to HO-1, its ability to modulate the expression of NF-B-dependent genes in EC seems to be mediated by bilirubin and/or by removal of intracellular Fe2+, but probably does involve the generation of CO.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Miguel P. Soares, Inflammation Laboratory, Instituto Gulbenkian de Ciência, Rua da Quinta Grande, 6, 2780-156 Oeiras, Portugal. E-mail address: mpsoares{at}igc.gulbenkian.pt
3 Current address: Department of Surgery, University of Hong Kong Medical Center, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.
4 Abbreviations used in this paper: EC, endothelial cell; HO-1, heme oxygenase-1; BAEC, bovine aortic EC; PAEC, porcine aortic EC; DFO, desferoxamine mesylate; SIH, salicylaldehyde isonicotinoyl hydrazone; RT, room temperature; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; -gal, -galactosidase.
Received for publication April 7, 2003. Accepted for publication December 15, 2003.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
B, an inhibitor of the transcription factor NF-B. J. Exp. Med. 183:1013.B to protect endothelial cells from tumor necrosis factor--mediated apoptosis. J. Biol. Chem. 277:17950.B. J. Clin. Invest. 99:763.[Medline]
B and cytokine-inducible enhancers. FASEB J. 9:899.[Abstract]
B activity. Annu. Rev. Immunol. 18:621.[Medline]
B is activated: the role of the IB kinase (IKK) complex. Oncogene 18:6867.[Medline]
B RelA phosphorylation and transcriptional activity by p21ras and protein kinase C
in primary endothelial cells. J. Biol. Chem. 274:13594.This article has been cited by other articles:
|
|
 |
|
  A. R. Kinderlerer, I. Pombo Gregoire, S. S. Hamdulay, F. Ali, R. Steinberg, G. Silva, N. Ali, B. Wang, D. O. Haskard, M. P. Soares, et al. Heme oxygenase-1 expression enhances vascular endothelial resistance to complement-mediated injury through induction of decay-accelerating factor: a role for increased bilirubin and ferritin Blood, February 12, 2009; 113(7): 1598 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bilban, P. Haslinger, J. Prast, F. Klinglmuller, T. Woelfel, S. Haider, A. Sachs, L. E. Otterbein, G. Desoye, U. Hiden, et al. Identification of Novel Trophoblast Invasion-Related Genes: Heme Oxygenase-1 Controls Motility via Peroxisome Proliferator-Activated Receptor {gamma} Endocrinology, February 1, 2009; 150(2): 1000 - 1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-T. Hsu, W.-H. Kan, C.-H. Hsieh, M. A. Choudhry, M. G. Schwacha, K. I. Bland, and I. H. Chaudry Mechanism of estrogen-mediated intestinal protection following trauma-hemorrhage: p38 MAPK-dependent upregulation of HO-1 Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2008; 294(6): R1825 - R1831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Lin, X.-M. Liu, K. Peyton, H. Wang, W.-C. Yang, S.-J. Lin, and W. Durante Far Infrared Therapy Inhibits Vascular Endothelial Inflammation via the Induction of Heme Oxygenase-1 Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 739 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Nemzek, C. Fry, and O. Abatan Low-dose carbon monoxide treatment attenuates early pulmonary neutrophil recruitment after acid aspiration Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L644 - L653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Morse and A. M. K. Choi Inhaled CO in the treatment of acute lung injury Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L642 - L643. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cepinskas, K. Katada, A. Bihari, and R. F. Potter Carbon monoxide liberated from carbon monoxide-releasing molecule CORM-2 attenuates inflammation in the liver of septic mice Am J Physiol Gastrointest Liver Physiol, January 1, 2008; 294(1): G184 - G191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Seldon, G. Silva, N. Pejanovic, R. Larsen, I. P. Gregoire, J. Filipe, J. Anrather, and M. P. Soares Heme Oxygenase-1 Inhibits the Expression of Adhesion Molecules Associated with Endothelial Cell Activation via Inhibition of NF-{kappa}B RelA Phosphorylation at Serine 276 J. Immunol., December 1, 2007; 179(11): 7840 - 7851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-T. Hsu, W.-H. Kan, C.-H. Hsieh, M. A. Choudhry, M. G. Schwacha, K. I. Bland, and I. H. Chaudry Mechanism of estrogen-mediated attenuation of hepatic injury following trauma-hemorrhage: Akt-dependent HO-1 up-regulation J. Leukoc. Biol., October 1, 2007; 82(4): 1019 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kronke, A. Kadl, E. Ikonomu, S. Bluml, A. Furnkranz, I. J. Sarembock, V. N. Bochkov, M. Exner, B. R. Binder, and N. Leitinger Expression of Heme Oxygenase-1 in Human Vascular Cells Is Regulated by Peroxisome Proliferator-Activated Receptors Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1276 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Urquhart, G. Rosignoli, D. Cooper, R. Motterlini, and M. Perretti Carbon Monoxide-Releasing Molecules Modulate Leukocyte-Endothelial Interactions under Flow J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 656 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Haschemi, O. Wagner, R. Marculescu, B. Wegiel, S. C. Robson, N. Gagliani, D. Gallo, J.-F. Chen, F. H. Bach, and L. E. Otterbein Cross-Regulation of Carbon Monoxide and the Adenosine A2a Receptor in Macrophages J. Immunol., May 1, 2007; 178(9): 5921 - 5929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. de Oliveira-Marques, L. Cyrne, H. S. Marinho, and F. Antunes A Quantitative Study of NF-{kappa}B Activation by H2O2: Relevance in Inflammation and Synergy with TNF-{alpha} J. Immunol., March 15, 2007; 178(6): 3893 - 3902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Georgiev, A A Navarini, J J Eloranta, K S Lang, G A Kullak-Ublick, A Nocito, F Dahm, W Jochum, R Graf, and P-A Clavien Cholestasis protects the liver from ischaemic injury and post-ischaemic inflammation in the mouse Gut, January 1, 2007; 56(1): 121 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stocker and M. A. Perrella Heme Oxygenase-1: A Novel Drug Target for Atherosclerotic Diseases? Circulation, November 14, 2006; 114(20): 2178 - 2189. [Full Text] [PDF]
|
|
|
|
|
|
K. R. Brunt, K. K. Fenrich, G. Kiani, M. Yat Tse, S. C. Pang, C. A. Ward, and L. G. Melo Protection of Human Vascular Smooth Muscle Cells From H2O2-Induced Apoptosis Through Functional Codependence Between HO-1 and AKT Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2027 - 2034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-P. Yu, S. Yang, Y.-C. Hsieh, M. A. Choudhry, K. I. Bland, and I. H. Chaudry Maintenance of lung myeloperoxidase activity in proestrus females after trauma-hemorrhage: upregulation of heme oxygenase-1 Am J Physiol Lung Cell Mol Physiol, September 1, 2006; 291(3): L400 - L406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Drechsler, A. Dolganiuc, O. Norkina, L. Romics, W. Li, K. Kodys, F. H. Bach, P. Mandrekar, and G. Szabo Heme Oxygenase-1 Mediates the Anti-Inflammatory Effects of Acute Alcohol on IL-10 Induction Involving p38 MAPK Activation in Monocytes J. Immunol., August 15, 2006; 177(4): 2592 - 2600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Silva, A. Cunha, I. P. Gregoire, M. P. Seldon, and M. P. Soares The Antiapoptotic Effect of Heme Oxygenase-1 in Endothelial Cells Involves the Degradation of p38{alpha} MAPK Isoform J. Immunol., August 1, 2006; 177(3): 1894 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fitau, G. Boulday, F. Coulon, T. Quillard, and B. Charreau The Adaptor Molecule Lnk Negatively Regulates Tumor Necrosis Factor-{alpha}-dependent VCAM-1 Expression in Endothelial Cells through Inhibition of the ERK1 and -2 Pathways J. Biol. Chem., July 21, 2006; 281(29): 20148 - 20159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Ryter, J. Alam, and A. M. K. Choi Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications Physiol Rev, April 1, 2006; 86(2): 583 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Szalay, T. Shimizu, T. Suzuki, H.-P. Yu, M. A. Choudhry, M. G. Schwacha, L. W. Rue III, K. I. Bland, and I. H. Chaudry Estradiol improves cardiac and hepatic function after trauma-hemorrhage: role of enhanced heat shock protein expression Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R812 - R818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-P. Yu, M. A. Choudhry, T. Shimizu, Y.-C. Hsieh, M. G. Schwacha, S. Yang, and I. H. Chaudry Mechanism of the salutary effects of flutamide on intestinal myeloperoxidase activity following trauma-hemorrhage: up-regulation of estrogen receptor-{beta}-dependent HO-1 J. Leukoc. Biol., February 1, 2006; 79(2): 277 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sollwedel, A. Z. Bertoja, M. L. Zenclussen, K. Gerlof, U. Lisewski, P. Wafula, B. Sawitzki, C. Woiciechowsky, H.-D. Volk, and A. C. Zenclussen Protection from Abortion by Heme Oxygenase-1 Up-Regulation Is Associated with Increased Levels of Bag-1 and Neuropilin-1 at the Fetal-Maternal Interface J. Immunol., October 15, 2005; 175(8): 4875 - 4885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Ogborne, S. A. Rushworth, and M. A. O'Connell {alpha}-Lipoic Acid-Induced Heme Oxygenase-1 Expression Is Mediated by Nuclear Factor Erythroid 2-Related Factor 2 and p38 Mitogen-Activated Protein Kinase in Human Monocytic Cells Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2100 - 2105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Nascimento-Silva, M. A. Arruda, C. Barja-Fidalgo, C. G. Villela, and I. M. Fierro Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells Am J Physiol Cell Physiol, September 1, 2005; 289(3): C557 - C563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Sullivan Stored Iron and Vascular Reactivity Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1532 - 1535. [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Bach Heme oxygenase-1: a therapeutic amplification funnel FASEB J, August 1, 2005; 19(10): 1216 - 1219. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Szalay, T. Shimizu, M. G. Schwacha, M. A. Choudhry, L. W. Rue III, K. I. Bland, and I. H. Chaudry Mechanism of salutary effects of estradiol on organ function after trauma-hemorrhage: upregulation of heme oxygenase Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H92 - H98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-O. Pae, G.-S. Oh, B.-M. Choi, Y.-M. Kim, and H.-T. Chung A Molecular Cascade Showing Nitric Oxide-Heme Oxygenase-1-Vascular Endothelial Growth Factor-Interleukin-8 Sequence in Human Endothelial Cells Endocrinology, May 1, 2005; 146(5): 2229 - 2238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Wong and A. J. Van der Kogel MECHANISMS OF RADIATION INJURY TO THE CENTRAL NERVOUS SYSTEM: IMPLICATIONS FOR NEUROPROTECTION Mol. Interv., October 1, 2004; 4(5): 273 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Arruda, A. G. Rossi, M. S. de Freitas, C. Barja-Fidalgo, and A. V. Graca-Souza Heme Inhibits Human Neutrophil Apoptosis: Involvement of Phosphoinositide 3-Kinase, MAPK, and NF-{kappa}B J. Immunol., August 1, 2004; 173(3): 2023 - 2030. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
), or transduced with 
) or HO-1 (•) recombinant adenoviruses and exposed to increasing concentrations of human rTNF-
) recombinant adenovirus and exposed to increasing concentrations of human rTNF-
) before being exposed to increasing concentrations of human rTNF-
) or exposed to TNF-
